Among the various subtypes of early‐stage invasive breast cancer (EBC), estrogen receptor‐positive, ERBB2‐negative (ER+/ERBB2‐) breast cancer accounts for approximately 60% of cases.2 Here, ERBB2 is linked to breast cancer.